Accession Number: | 0001562180-23-002037 |
Date: | 2023-02-27 |
Issuer: | AKEBIA THERAPEUTICS, INC. (AKBA) |
Original Submission Date: |
HADAS NICOLE R.
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST STREET
CAMBRIDGE, MA 02142
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2023-02-27 | S | 6,677 | d | $0.81 | 300,564 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | this sale was made automatically by the issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on february 26, 2021. |
f2 | includes 1,500 shares of the issuers common stock purchased on june 30, 2022, and 1,500 shares of the issuers common stock purchased on december 30, 2022, each under the issuer's 2014 amended and restated employee stock purchase plan. |